Japanese pharmaceutical company Shionogi & Co., Ltd., has selected Cloudera to boost its data analytics ca...
French firm Iktos, a company specialized in Artificial Intelligence (AI) for new drug design, and Japan's Teij...
US' Halozyme Therapeutics has announced a global collaboration and license agreement with Japan's Chugai Pharmaceutical ...
Otsuka Pharmaceutical has announced that its collaborator Akebia Therapeutics, Inc. (Akebia) has submitted a New Drug Ap...
PENTAX Medical, a division of HOYA Group, has announced the appointment of Rainer Burkard to the position of Global Pres...
Japan's Terumo Corporation and US-based Glooko have announced a technology integration to deliver new diabetes...
The Japanese Ministry of Health, Labor, and Welfare (MHLW) has granted marketing authorisation for Xenpozyme (olipu...
Daiichi Sankyo Company has obtained approval in Japan to change the indication of the analgesic 'Tarlige Tablets' (mirog...
Takeda has received approval from the Ministry of Health, Labour and Welfare (MHLW) for TAKHZYRO (lanadelumab) subc...
Health2Sync and Novo Nordisk Pharma Ltd. are partnering in Japan to support digital diabetes management and facilitate c...
Shanghai MicroPort Endovascular MedTech has received registration approval from Japan Pharmaceuticals and Medical Device...
TANAKA Kikinzoku Kogyo KK which operates the TANAKA precious metals manufacturing business announced that TANAKA has dev...
Japan-based Elix, Inc., an AI drug discovery company, has commenced joint research on the retrosynthetic analysis module...
Japan-based FUJIFILM Corporation has announced that FUJIFILM Irvine Scientific, Inc., a world leader in the development ...
The National Institutes of Biomedical Innovation, Health and Nutrition (NIBIOHN), based in Japan, has successfully&...
Biogen Inc. and Eisai Co., Ltd. announced that the companies have amended their existing collaboration agreement on aduc...
Singapore's NDR Medical (NDR), the leading interventional robotics company, extended its Asia-Pacific presence with the ...
Japan-based Astellas Pharma Inc. has announced topline results from the ongoing Phase 3 MOONLIGHT 1 clinical trial inves...
